WellSpring Pharma Services has completed a $3 million capital investment in new equipment and has entered a strategic partnership with IDT Australia Ltd. to manufacture drugs for the U.S. market.
 
The investment adds capabilities in smaller development-scale equipment, expanded manufacturing for specialized dosage forms, such as bilayer tablets, and improved support for high-potency compound manufacturing. New equipment includes: an Alexanderwerk Roller Compactor; an IMA Precisa capsule weight checker; a 400 kg O’Hara Tray Drying oven; a Korsch XL 400 Tablet Press with bilayer module; a Glatt GPCG 2/5 Fluid Bed Processor; an O’Hara Aqueous Film Coater with 18” and 30” interchangeable pans; and a 5L Becomix Counter sweep vessel.

Additionally, WellSpring signed a manufacturing and supply agreement to produce several products for IDT Australia at its facility near Toronto, including Pindolol, a cardiac drug with an estimated U.S. market value of $10 million.
 
“Our expanded capabilities include new expertise in process development and manufacturing for earlier phased clinical trials as well as future expansion of our large-scale manufacturing capabilities,” said David Mayers, president, WellSpring Pharma Services. “We’re now better equipped to offer our clients services from small-scale development and scale-up to large-scale manufacturing, packaging and distribution.”